Company registration number 14093411 (England and Wales)
THERAPORT LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MAY 2023
PAGES FOR FILING WITH REGISTRAR
THERAPORT LTD
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 5
THERAPORT LTD
BALANCE SHEET
AS AT 31 MAY 2023
31 May 2023
- 1 -
2023
Notes
£
£
Current assets
Debtors
5
561
Creditors: amounts falling due within one year
6
(1,928)
Net current liabilities
(1,367)
Capital and reserves
Called up share capital
7
1
Share premium account
10,003
Profit and loss reserves
(11,371)
Total equity
(1,367)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial period ended 31 May 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 6 February 2024 and are signed on its behalf by:
Miss A Huhn
Director
Company Registration No. 14093411
THERAPORT LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 MAY 2023
- 2 -
Share capital
Share premium account
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 9 May 2022
-
0
-
0
-
0
-
Period ended 31 May 2023:
Loss and total comprehensive income for the period
-
-
(11,371)
(11,371)
Issue of share capital
7
1
10,003
-
10,004
Balance at 31 May 2023
1
10,003
(11,371)
(1,367)
THERAPORT LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MAY 2023
- 3 -
1
Accounting policies
Company information

Theraport Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 34 High Street, Aldridge, Walsall, West Midlands, WS9 8LZ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Research and development expenditure

Research and development expenditure is written off against profits in the year in which it is incurred.

1.4
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include other debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

THERAPORT LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MAY 2023
1
Accounting policies
(Continued)
- 4 -
Basic financial liabilities

Basic financial liabilities, including other creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

1.5
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

1.6
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

1.7
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.8
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2023
Number
Total
1
4
Directors' remuneration
2023
£
Remuneration paid to directors
6,000
THERAPORT LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MAY 2023
- 5 -
5
Debtors
2023
Amounts falling due within one year:
£
Other debtors
561
6
Creditors: amounts falling due within one year
2023
£
Other creditors
1,928
7
Called up share capital
2023
2023
Ordinary share capital
Number
£
Issued and fully paid
Ordinary Shares of 0.01p each
11,350
1

During the period, 11,350 Ordinary 0.01p shares were issued for a total consideration of £10,004.

 

8
Events after the reporting date

After the reporting date the company issued 1,500 Ordinary 0.01p shares for a total consideration of £30,000.

 

2023-05-312022-05-09false06 February 2024CCH SoftwareCCH Accounts Production 2023.300No description of principal activityMiss A HuhnMr T N PrescodMiss A E Thomasfalse140934112022-05-092023-05-31140934112023-05-3114093411core:CurrentFinancialInstrumentscore:WithinOneYear2023-05-3114093411core:ShareCapital2023-05-3114093411core:SharePremium2023-05-3114093411core:RetainedEarningsAccumulatedLosses2023-05-3114093411core:ShareCapital2022-05-0814093411core:SharePremium2022-05-0814093411core:RetainedEarningsAccumulatedLosses2022-05-0814093411bus:Director12022-05-092023-05-3114093411core:RetainedEarningsAccumulatedLosses2022-05-092023-05-3114093411core:ShareCapital2022-05-092023-05-3114093411core:SharePremium2022-05-092023-05-3114093411core:WithinOneYear2023-05-3114093411core:CurrentFinancialInstruments2023-05-3114093411bus:PrivateLimitedCompanyLtd2022-05-092023-05-3114093411bus:SmallCompaniesRegimeForAccounts2022-05-092023-05-3114093411bus:FRS1022022-05-092023-05-3114093411bus:AuditExemptWithAccountantsReport2022-05-092023-05-3114093411bus:Director22022-05-092023-05-3114093411bus:Director32022-05-092023-05-3114093411bus:FullAccounts2022-05-092023-05-31xbrli:purexbrli:sharesiso4217:GBP